NCT02480101View on ClinicalTrials.gov

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

April 30, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

H7N9 live influenza vaccine

H7N9 live influenza vaccine

BIOLOGICAL

Placebo

Lyophilized purified allantoic fluid of chicken embryos with stabilizers

All Listed Sponsors
collaborator

World Health Organization

OTHER

collaborator

Institute of Experimental Medicine, Russia

OTHER

lead

Research Institute of Influenza, Russia

OTHER

NCT02480101 - Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine | Biotech Hunter | Biotech Hunter